ADAR1 Capital Management, LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001940272
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2024 · 250 positions · Total reported value $413.07M · Top-10 concentration 58.7% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 47.5% · 33 new · 62 cut · 48 exited
Active Share (vs S&P 500): 98.9% · vs QQQ: 99.4% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -7.0% · vs SPY -9.1% · Prev Value $1.81B — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -3.7% · vs SPY -5.9% · Latest Value $1.82B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q2 2024 13F filing, ADAR1 Capital Management, LLC disclosed 250 equity positions with a combined reported value of $413.07M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 58.7% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2024 were PTGX ($55.58M), ROIV ($43.87M), BOXX ($37.90M). By sector, the heaviest allocations are Health Care 74.5%, Consumer Discretionary 0.3%. Versus the prior quarter, allocation shifted toward Health Care (+15.2pp) and away from Consumer Staples (-0.5pp), Other (-14.8pp).
Versus the prior quarter, ADAR1 Capital Management, LLC opened 33 new positions, trimmed 62 and fully exited 48, a turnover rate of 47.5% of positions. The portfolio's overlap with the prior quarter was 62% of names.
The largest new positions opened in Q2 2024 were RZLT ($8.88M), PCSC ($7.54M), TECX ($5.88M).
Of the 48 positions fully exited versus the prior quarter, the largest were MACK ($13.33M), AVRO ($5.06M), FUSN ($3.78M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2024)
- RZLT REZOLUTE INC · $8.88M
- PCSC PERCEPTIVE CAP SOLUTIONS COR · $7.54M
- TECX TECTONIC THERAPEUTIC INC · $5.88M
- CRNX CRINETICS PHARMACEUTICALS IN · $3.35M
- KALA KALA BIO INC · $2.17M
- BEAM BEAM THERAPEUTICS INC · $1.71M
- SLNO SOLENO THERAPEUTICS INC · $1.63M
- MRUS MERUS N V · $1.59M
Fully Exited (vs previous quarter)
- MACK MERRIMACK PHARMACEUTICALS IN · prev qtr: $13.33M
- AVRO AVROBIO INC · prev qtr: $5.06M
- FUSN FUSION PHARMACEUTICALS INC · prev qtr: $3.78M
- REGN REGENERON PHARMACEUTICALS · prev qtr: $2.21M · history
- SDGR SCHRODINGER INC · prev qtr: $1.72M
- LLY ELI LILLY & CO · prev qtr: $1.45M
- NGM NGM BIOPHARMACEUTICALS INC · prev qtr: $1.30M
- GLST GLOBAL STAR ACQUISITION-CL A · prev qtr: $856.80K
Insider Transactions (Form 4)
Latest ADAR1 Capital Management, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-11-11 | Buy | NextCure, Inc. | 12,333 | $5.10 | SEC filing |
| 2026-11-06 | Buy | NextCure, Inc. | 3,662 | $5.10 | SEC filing |
| 2026-11-05 | Buy | InMed Pharmaceuticals Inc. | 2,640 | $13.10 | SEC filing |
| 2026-11-05 | Buy | NextCure, Inc. | 1,024 | $5.10 | SEC filing |
| 2026-10-27 | Buy | NextCure, Inc. | 3,553 | $5.10 | SEC filing |
| 2026-10-26 | Buy | NextCure, Inc. | 1,672 | $5.03 | SEC filing |
| 2026-10-23 | Buy | InMed Pharmaceuticals Inc. | 4 | $1.32 | SEC filing |
| 2026-10-23 | Buy | NextCure, Inc. | 5,626 | $4.83 | SEC filing |
Fund Profile
ADAR1 Capital Management, LLC is an SEC-registered 13F filer based in Austin, TX, United States. As of Q2 2026 it reported 268 US equity positions with a combined value of $1.81B. HoldingsHub carries 11 quarters of its filings (Q4 2023–Q2 2026).
Firm Snapshot
- Headquarters: AUSTIN, TX, United States
- SEC registration: 801-130082 (status: Approved), registered 2024-04-25
- Regulatory AUM (Form ADV): $1.68B as of 2026-03-31
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 2 private funds, of which 2 hedge funds
Portfolio Structure
- 268 positions · $1.81B reported value (Q2 2026)
- Top 10 holdings = 34.2% of reported value
- Largest position: PTGX (PROTAGONIST THERAPEUTICS INC) at 6.5%
- Average position size: $6.74M
Sector Tilt
- Health Care 86.5%
- Financials 2.6%
- Industrials 0.4%
- (classified holdings cover 90% of value)
Quarterly Activity
- Q2 2026: 42 new, 99 added, 60 reduced, 69 exited
- 67 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
Sector Allocation
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
1.60M | $55.58M | 13.46% | Add | |
| 2 |
|
4.15M | $43.87M | 10.62% | Add | |
| 3 |
|
351.48K | $37.90M | 9.17% | Add | |
| 4 |
|
1.18M | $31.15M | 7.54% | Add | |
| 5 |
|
548.92K | $25.09M | 6.07% | Add | |
| 6 |
|
476.54K | $12.58M | 3.05% | Add | |
| 7 |
|
3.29M | $10.16M | 2.46% | Add | |
| 8 |
|
75.75K | $9.38M | 2.27% | Add | |
| 9 |
|
2.06M | $8.88M | 2.15% | New | |
| 10 |
|
1.42M | $8.05M | 1.95% | Add | |
| 11 |
|
436.61K | $7.86M | 1.90% | Add | |
| 12 |
|
750.00K | $7.54M | 1.83% | New | |
| 13 |
|
51.26K | $6.99M | 1.69% | Add | |
| 14 |
|
356.88K | $5.88M | 1.42% | New | |
| 15 |
|
1.22M | $5.48M | 1.33% | Add | |
| 16 |
|
1.70M | $5.23M | 1.27% | Add | |
| 17 |
|
91.23K | $4.84M | 1.17% | Add | |
| 18 |
|
196.58K | $4.74M | 1.15% | Add | |
| 19 |
|
8.00K | $4.35M | 1.05% | Reduce | |
| 20 |
|
404.14K | $4.13M | 1.00% | Hold | |
| 21 |
|
74.85K | $3.35M | 0.81% | New | |
| 22 |
|
32.50K | $2.98M | 0.72% | Hold | |
| 23 |
|
42.22K | $2.83M | 0.69% | Add | |
| 24 |
|
156.50K | $2.81M | 0.68% | Reduce | |
| 25 |
|
959.57K | $2.80M | 0.68% | Add | |
| 26 |
|
55.21K | $2.73M | 0.66% | Hold | |
| 27 |
|
54.00K | $2.73M | 0.66% | Hold | |
| 28 |
|
24.50K | $2.71M | 0.66% | Hold | |
| 29 |
|
712.56K | $2.67M | 0.65% | Add | |
| 30 |
|
53.00K | $2.67M | 0.65% | Hold | |
| 31 |
|
542.23K | $2.55M | 0.62% | Reduce | |
| 32 |
|
253.20K | $2.29M | 0.55% | Add | |
| 33 |
|
306.07K | $2.17M | 0.53% | New | |
| 34 |
|
114.31K | $2.13M | 0.52% | Add | |
| 35 |
|
50.20K | $2.05M | 0.50% | Add | |
| 36 |
|
47.68K | $1.93M | 0.47% | Hold | |
| 37 |
|
72.80K | $1.71M | 0.41% | New | |
| 38 |
|
682.09K | $1.71M | 0.41% | Add | |
| 39 |
|
103.12K | $1.68M | 0.41% | Add | |
| 40 |
|
198.35K | $1.66M | 0.40% | Reduce | |
| 41 |
|
39.93K | $1.63M | 0.39% | New | |
| 42 |
|
40.88K | $1.61M | 0.39% | Add | |
| 43 |
|
26.85K | $1.59M | 0.39% | New | |
| 44 |
|
11.10K | $1.58M | 0.38% | Reduce | |
| 45 |
|
203.24K | $1.54M | 0.37% | New | |
| 46 |
|
50.63K | $1.51M | 0.37% | Add | |
| 47 |
|
320.73K | $1.50M | 0.36% | Add | |
| 48 |
|
3.00K | $1.44M | 0.35% | Reduce | |
| 49 |
|
645.16K | $1.29M | 0.31% | Add | |
| 50 |
|
138.16K | $1.26M | 0.30% | Add | |
FAQ
What did ADAR1 Capital Management, LLC buy in 2024-Q2?
In its 2024-Q2 13F filing, ADAR1 Capital Management, LLC reported 250 equity positions worth $413.07M in aggregate; its largest disclosed positions were PTGX ($55.58M), ROIV ($43.87M), BOXX ($37.90M).
How large is ADAR1 Capital Management, LLC's portfolio?
ADAR1 Capital Management, LLC reported $413.07M of long equity holdings across 250 positions as of 2024-Q2. Top-10 holdings account for 58.7% of reported value.
What is ADAR1 Capital Management, LLC's investment style?
HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.